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ACKGROUND: Cytochrome P450 (CYP) 
enzymes play important roles in human, including 
drug metabolism. CYP2 is the largest family of 
human CYP, with its sequence comprising almost one third 
of all CYP sequences, and responsible for the metabolism of 
approximately 2% of clinically administrated drugs. One of 
the most important enzymes in this family is the CYP2C19 
enzyme. The CYP2C19 gene is polymorphic, and the 
variation is common especially in the Asian population.
CONTENT: CYP2C19 is responsible for the metabolism 
of various drugs, including proton pump inhibitors (PPIs) 
such as omeprazole and lansoprazole, psychotropic drugs 
including diazepam and imipramine, anticonvulsants 
such as phenobarbital and mephenytoin. and the recently 
most studied the anti-platelet drug, clopidogrel, and many 
others. Drugs metabolized predominantly by this enzyme 
like clopidogrel and PPIs might be much affected by the 
genotype status of CYP2C19. Clopidogrel is a pro-drug 
requiring a group of enzymes to convert to its active form, 
particularly the CYP2C19. PPIs are metabolized to its 
inactive metabolites mainly by CYP2C19 in the liver. Some 
PPIs are inhibitor of CYP2C19 enzymes, and interaction of 
PPIs and clopidogrel has been widely studied.
SUMMARY: The association of CYP2C19 genotypes with 
the plasma level of active clopidogrel and platelet reactivity 
in individual taking this drug is well-established. Although 
conlicting results still exist for the association of CYP2C19 
genotypes to the clinical outcomes of clopidogrel therapy, 
this effect seems to be consistent in patients receiving 
clopidogrel for coronary stents. Due to the interaction of 
certain PPIs and clopidogrel, the use of PPIs other than 
omeprazole is recommended, especially for patients taking 
L
ATAR BELAKANG: Enzim sitokrom P450 (CYP) 
berperan penting pada manusia, termasuk salah 
satunya dalam metabolisme obat-obatan. CYP2 
adalah famili CYP yang terbesar pada manusia, dengan 
panjang urutan gennya mencapai sepertiga dari seluruh 
gen CYP, serta bertanggungjawab terhadap metabolism 
dari kurang lebih 20 % dari seluruh obat-obatan. Salah satu 
enzim yang paling penting dalam family CYP2 ini adalah 
enzim CYP2C19. Gen CYP2C19 bersifat polimorik, dan 
variasi ini terutama umum dijumpai pada populasi Asia.
ISI: CYP2C19 bertanggungjawab terhadap metabolisme 
serangkaian obat, termasuk penghambat pompa proton (PPI) 
seperti omeprazole dan lansoprazole, obat psikotropika 
seperti diazepam dan imipramine, antikonvulsan seperti 
phenobarbital dan mephenytoin, dan yang paling banyak 
dipelajari sekarang ini, obat anti-platelet, clopidogrel, serta 
yang lainnya. Obat-obat yang dimetabolisme oleh enzim ini 
seperti clopidogrel dan penghambat pompa proton sangat 
dipengaruhi oleh status genotipe dari CYP2C19. Clopidogrel 
adalah suatu pro-drug yang memerlukan sekelompok enzim 
untuk terkonversi menjadi bentuk aktifnya, terutama enzim 
CYP2C19. PPI dimetabolisme menjadi metabolit inaktif 
terutama oleh enzim CYP2C19 di dalam hati. Beberapa 
jenis PPI merupakan inhibitor dari enzim CYP2C19, dan 
interaksi antara PPI dengan clopidogrel telah banyak 
dipelajari. 
RINGKASAN: Hubungan antara genotipe CYP2C19 
dengan kadar aktif clopidogrel dan reaktivitas clopidogrel 
pada individu yang mengkonsumsi obat ini sudah sangat 
jelas. Walaupun terdapat laporan yang saling bertentangan 
tentang hubungan antara genotipe CYP2C19 dengan data 
klinis dari terapi clopidogrel, efek ini tampaknya konsisten 
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Introduction
number is much smaller compared those observed in plants 
and animals, for example there are 323 genes in rice (Oryza 
sativa) and 102 genes in mouse.(7)
 A systematic nomenclature scheme for the CYP gene 
superfamily was published in 1987.(8) CYP proteins are 
conveniently arranged into families and subfamilies on the 
basis of percentage of amino acid sequence identity. Enzymes 
that share ≥40 % identity are assigned to a particular family 
designated by an Arabic numeral, whereas those sharing 
≥55% identity make up a particular subfamily designated 
by a letter.(5) But, this assignation also greatly depends on 
how the sequence clusters on a tree and not so much for 
the absolute percentage.(9) Enzymes with more than 97% 
identical are considered to represent alleles unless there is 
evidence to the contrary. A complete database of CYP can 
be found at http://drnelson.uthsc.edu/CytochromeP450.
html.(7)
Human CYP enzymes are expressed on the smooth 
endoplasmic reticulum of cells throughout the body, with the 
highest concentrations to be found in the liver (hepatocytes) 
and small intestine.(10) They are grouped in 18 families 
and 43 subfamilies (7), with the irst three families, CYP1, 
CYP2, and CYP3 being of the most importance (11).
Metabolism of drugs, particularly the phase I oxidation is 
probably the most well-known function of CYP in humans. 
CYP superfamily that metabolizes these substances in the 
human body is almost exclusively the 3 families of CYP1, 
CYP2 and CYP3 family, and to a lesser degree CYP4.(1,5) 
Six enzymes, CYP1A2, CYP2C9, CYP2C19, CYP2D6, 
CYP3A4 and CYP3A5, metabolize 90% of drugs.(6)
 CYP2 is the largest family of human CYP, with its 
dual anti platelet therapy of clopidogrel and aspirin. 
KEYWORDS: pharmacogenetics, CYP2C19, proton pump 
inhibitors, clopidogrel
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pada pasien dengan stent koroner yang mendapatkan 
clopidogrel. Karena interaksi antara sebagian PPI dengan 
clopidogrel, penggunaan PPI selain omeprazole disarankan, 
terutama pada pasien yang mendapatkan terapi anti platelet 
gabungan, clopidogrel dan aspirin.
KATA KUNCI:  farmakogenetik, CYP2C19, penghambat 
pompa proton , clopidogrel
Pharmacogenetics is a term to describe how the gene 
sequence can affect the response of an individual to certain 
drugs or medication. One of the largest and most functional 
diverse genes is the Cytochrome P450 (CYP) enzymes.(1) 
Of this family, CYP2C19 especially plays signiicant role in 
Asian population due to its higher mutation rate. CYP2C19 
is an enzyme essential for metabolism of some clinically 
important drugs such as clopidogrel, proton pump inhibitor 
(PPI) and some antidepressant.(2,3) FDA has approved new 
information on the label of clopidogrel regarding the genetic 
test for CYP2C19, as well as the potential interaction 
between clopidogrel and PPI, especially omeprazole.(4) 
In this review article, we discuss current evidence on the 
inluence of CYP2C19 polymorphism to the outcomes of 
clopidogrel treatment, as well as the interaction with PPIs.
CYP enzymes family is one of the largest and most diverse 
superfamily, found in numerous living organism, from 
bacteria to humans, with remarkable functions.(1) In human, 
CYP plays various roles, including metabolism of drugs 
and foreign chemicals, metabolism of arachidonic acid and 
eicosanoids, metabolism of cholesterol and biosynthesis of 
bile acid, synthesis and metabolism of steroids, synthesis 
and metabolism of vitamin D3, hydroxylation of retinoid 
acid, the conversion of procarcinogens and promutagens to 
deleterious genotoxic compounds, and some still unknown 
functions.(1,5) This enzymes family was irst named in 1961 
when they were found to be bound to membranes within a 
cell (cyto) and contain a heme pigment (chrome and P) that 
absorbs light at a wavelength of 450 nm when exposed to 
carbon monoxide.(5,6) Human CYP superfamily comprises 
57 functionally active genes, and 58 pseudogenes. This 
CYP
Human CYP Family
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sequence comprising almost one third of all CYP sequences.
(1) Of the CYP213 subfamilies, CYP2C enzymes are 
responsible for the metabolism of approximately 20% of 
clinically administrated drugs. Three enzymes from this 
subfamily are of most clinical importance, i.e. CYP2C8, 
CYP2C9 and CYP2C19.(1)
CYP2C19 enzymes are responsible for the metabolism 
of various drugs, including PPIs such as omeprazole and 
lansoprazole, psychotropic drugs including diazepam 
and imipramine, anticonvulsants such as phenobarbital 
and mephenytoin. and the most studied recently the anti-
platelet drug, clopidogrel, and many others.(2,3) CYP2C19 
gene is located in chromosome 10 (10q24) and encodes a 
490-amino-acid protein.(7,12) CYP2C19 and CYP2C9 
genes are located in the same chromosome and the enzymes 
share a 91% structural similarity.(2)
 All enzymes in the CYP2C subfamily are found to 
be genetically polymorphic.(13) Genetic polymorphism is 
deined as a mutation in the DNA sequence which is present 
in at least 1% of the population. The polymorphism can 
exist as deletion, insertion or single base substitution, or also 
known as Single Nucleotide Polymorphism (SNP). These 
SNPs can result in the change in the amino acid sequence, 
premature stop codon, or a splicing defect that can increase, 
decrease, or diminish the protein function. 
 In general, four phenotypes can be identiied: poor 
metabolizers (PMs), who lack the functional enzyme; 
intermediary metabolizers (IMs), who are heterozygous for 
one loss of function allele or carry two alleles that cause 
reduced activity; extensive metabolizers (EMs), who have 
two normal alleles; and ultrarapid metabolizers (UMs) who 
acquire the gain of function allele.(11)
 The irst polymorphism discovered in the CYP2C 
subfamilies was the well-known polymorphism of CYP2C19 
in the metabolism of the anticonvulsant drug mephenytoin.
(13) To date, at least 34 alleles of CYPC19 have been 
identiied (*1 to *34) with several subvariants within the 
same allele.(14) CYP2C19*1 is designated for the normal 
or wild-type allele and exhibits normal function (EM). From 
the numerous variants only a small number of variations 
give signiicance in terms of clinical and frequency.(14) 
The loss of function allele (CYP2C19*2) was irst reported 
by de Morais et al. in 1994. They found that a single base 
pair (G>A) mutation in exon 5 of CYP2C19 (rs4244285), 
which creates an aberrant splice site is the major genetic 
defect that affects the metabolism of mephenytoin.(15) 
This mutation results in mRNA lacking the irst 40 bp of 
exon 5, producing a premature stop codon and a truncated 
234 amino acid protein lacking the heme-binding region. 
Later in the same year, the same group reported the second 
most common allele, the CYP2C19*3, with a change from 
G>A at position 636 of exon 4 of CYP2C19 (rs4986893), 
which creates a premature stop codon.(16) Both of these 
alleles result in a defective nonfunctional enzyme, with 
a phenotype of PM. CYP2C19*2 and CYP2C19*3 are 
the most frequent mutated alleles of this enzyme, and the 
frequency varies throughout different ethnics. In Asian 
population, these two polymorphisms account for more than 
99% of all polymorphisms detected. (17,18)
 Another polymorphism of clinical signiicance is the 
CYP2C19*17, which is a gain of function polymorphism, 
carrying -806 C>T and -3402 C>T mutation in the 5′-lanking 
region of the gene (12), and increase the transcription 
level (19). In the irst report, this polymorphism cause 
CYPʹCͳͻ
Asian Caucasian African American
1 CYP2D6 CYP2D6*3 <1% <1–9% <1%
(25) CYP2D6*4 <1–9% >10% <1–9%
CYP2D6*5 1–9% 1–9% <1–9%
CYP2D6*6 < 1 % < 1 % < 1 %
2 CYP2C9 CYP2C9*2 0 13% 3%
(22) CYP2C9*3 4% 7% 2%
3 CYP2C19 CYP2C19*2 30.50% 1.20-1.40% 1.20-1.79%




Table 1. Common loss of function polymorphisms of CYP2D6, 
CYP2C9, and CYP2C19 and their frequency in different races. 
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UM enzymes and results in lower level of omeprazole or 
mephenytoin, increasing the risk of treatment failure with 
these drugs.(20) Study correlating this mutation to the 
treatment with clopidogrel revealed that individual carrying 
this polymorphism had enhanced response to  clopidogrel 
and  an increased risk of bleeding.(21) 
 The polymorphism of CYP2C19 may be the most 
important in the Asian population due to its higher allelic 
frequency, compared to the other enzymes in this family, for 
example, CYP2C9, and CYP2D6. Table 1 shows the three 
enzymes that are important in human drug metabolism, 
together with their common polymorphisms and frequency 
in different races.(22-25) Our in-house data showed the 
allelic frequency of CYP2C19*2 and CYP2C19*3 as high 
as 24% and 4%, respectively.(26)
Clopidogrel is one of the most widely prescribed drugs in the 
world. It is used in the management of cardiocerebrovascular 
diseases, including acute coronary syndrome, myocardial 
infarction, stroke, and also in patients undergoing 
percutaneous coronary intervention. (3,4) Clopidogrel is 
often prescribed as dual therapy with aspirin, another anti-
platelet agent.(3,27) Inter-individuality variation in the 
response of clopidogrel has been observed, and the term of 
clopidogrel resistance, nonresponders, poor responders is 
also known.(28) Clopidogrel is a thienopyridine derivate, 
and administrated as a pro-drug that requires metabolism 


















Figure 1. Conversion of Clopidogrel into its active metabolites.
After administered, clopidogrel is absorbed in the intestinal, 
regulated by ATP-binding cassette, sub-family B, member 
1 (ABCB1) transporter located on the cell surface of 
intestinal epithelial cells. Once absorbed, approximately 
85% of clopidogrel is metabolized into inactive forms, 
via hydrolysis in the liver by esterase. The remaining 15% 
will be converted into its active form (3), and then binds 
speciically and irreversibly to the platelet P2Y12 Receptor, 
inhibiting adenosine diphosphate (ADP)-mediated platelet 
activation and aggregation (28). 
 The conversion of clopidogrel into its active form also 
occurs in the liver via a 2-step oxidation processes. These 
processes require CYP enzymes.(3)  The irst reaction is the 
conversion of clopidogrel into 2-oxo clopidogrel and the 
second is the conversion from 2-oxo clopidogrel to the active 
metabolites of clopidogrel (R-130964). The two processes 
are mediated by different enzymes. Kazui et al., did a study 
to identify the enzymes involved in those two processes 
and they found that the irst step was catalysed mainly by 
CYP2C19 (44.9%), followed by CYP1A2 (35.8%) and 
CYP2B6 (19.4%), and the second step involved another 
enzymes of CYP, namely CYP3A4 (39.8%), CYP2B6 
(32.9%), CYP2C19 (20.6%), and CYP2C9 (6.76%).(29) 
This study’s results conirm the importance of CYP2C19 
enzyme in the metabolism of clopidogrel. Polymorphism of 
CYP2C19 is also the most thoroughly investigated among 
the others, in regard of the response of clopidogrel.
 Polymorphisms of CYP2C19 have pharmacokinetic 
and pharmacodynamic effects upon intake of clopidogrel, 
and these effects were observed during loading doses 
(either 300 or 600 mg) as well as during the administration 
CYPʹCͳͻ - Effects on Clopidogrel
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of a maintenance dose.(30)  A number of studies have 
noted the signiicance of CYP2C19 polymorphism in this 
phenomenon.(30-32)
 It has been shown that CYP2C19 with even 
heterozygote loss of function allele (e.g. CYP2C19*1/*2) 
gives lower responsiveness to clopidogrel compared to the 
wild-type allele (*1/*1) (p < 0.003).(31) This polymorphism 
also correlates with the plasma level of active clopidogrel. 
(32) But to be noted, Hulot et al. have also found that 2 
of 7 subjects in their study with the weakest response to 
clopidogrel have the wild-type genotype of CYP2C19. 
(31) Other studies also found that the polymorphism of 
CYP2C19 can only explain for 12-20% of total variability 
of clopidogrel response.(33,34) This indicates that response 
to clopidogrel is affected by other genetic or non-genetic 
factors. Several factors that have been reported are age, 
body mass index, diabetes, dyslipidemia, and others.(18)
Numerous studies have been conducted to investigate the 
effects of CYP2C19 polymorphism in clopidogrel response 
toward the clinical signiicance.(30,33,35-39) These studies 
did not only correlate this polymorphism with the plasma 
level of active clopidogrel or the platelet reactivity measured 
by some methods, but also correlate it further to the clinical 
outcomes, in short and long terms prospective studies. 
 Some studies have found the relative risk as high as 
10 times for the loss of function CYP2C19 compared to 
wild-type (35), and others have also reported insigniicant 
correlation (36,40).
 Some meta-analyses and systematic review have 
been conducted to have a better look on the different 
results by different studies. Mega et al. in 2010 did a meta-
analysis of 9 studies (cohort studies and clinical outcomes) 
in which clopidogrel was initiated in predominantly 
invasively managed patients. They concluded that there 
was a signiicant increased risk of the composite end point 
of cardiovascular death, myocardial infarction or stroke 
in carrier of 1 reduced-function CYP2C19 allele with the 
hazard ratio (HR) of 1.55 (95%CI: 1.11-2.17, p=0.01) 
and in carrier of 2 reduced-function with the HR of 1.76 
(95%CI: 1.24-2.50, p=0.02). They also correlated it with 
stent thrombosis as the end point, and found the HR of 2.67 
(95% CI: 1.69-4.22, p<0.0001) and HR of 3.95 (95%CI: 
1.75-9.02, p=0.001) for carrier of 1 and 2 reduced-function 
CYP2C19 allele, respectively.(41)
 Another meta-analysis by Soi et al. in 2011 in 7 
cohort studies, involving 8,043 patients that were followed 
for a period of time ranging from 6 months to 8.3 years 
also concluded a signiicant association between the 
CYP2C19*2 polymorphism and the increased risk of major 
adverse cardiovascular events with a relative risk (RR) of 
1.96 (95%CI: 1.14-3.37, p=0.02), and with the increased 
risk of stent thrombosis with a RR of 3.82 (95%CI: 2.23-
6.54, p=0.0001).(42)
 Two other meta-analyses reported quite similar 
conclusion with each other. Bauer et al. in 2011 analyzed 15 
studies that met their criteria of full length reports assessing 
the cumulative incidence of major adverse cardiovascular 
events or stent thrombosis over a follow-up period of at 
least a month in association with carrier status for the loss of 
function or gain of function CYP2C19 allele with coronary 
artery disease and a clinical presentation of acute coronary 
syndrome or stable angina pectoris who were taking 
clopidogrel. They reported the odds ratio (OD) of 1.77 
(95%CI: 1.31-2.40, p<0.001) for stent thrombosis in carriers 
of at least one CYP2C19 loss of function allele versus 
non-carriers combining 9 studies, but after the adjustment 
for small study effect bias and replication diversity, the 
association was abolished. The OD of major adverse 
cardiovascular events for 12 studies combined was 1.11 
(95%CI: 0.89-1.39, p=0.36). The OD of stent thrombosis 
in carriers versus non-carriers of at least one CYP2C19*17 
gain of function allele for three studies combined was 0.99 
(95%CI: 0.60-1.62, p=0.96), and the corresponding OD of 
major adverse cardiovascular events in 5 studies was 0.93 
(95%CI: 0.75-1.14, p=0.48).(43)
 Holmes et al. in 2011 analysed 32 studies, consisting 
of 6 randomized trial and 26 treatment only design. In 
treatment only studies, they found a higher risk of CVD 
events in individuals with 1 or more CYP2C19 alleles 
associated with lower enzyme activity with a relative 
risk of 1.18 (95%CI: 1.09-1.28), an absolute risk increase 
of 8-12 events per 1,000 individuals. To adjust the small 
study bias, they restricted the analysis to studies with 
200 or more events, and found that the association was 
attenuated (RR 0.97; 95%CI: 0.86-1.09). But they found 
no association of CYP2C19 genotype with the CVD end 
point in effect modiication studies. As a conclusion, they 
stated that there was an association between CYP2C19 
genotype and clopidogrel responsiveness, shown by less 
clopidogrel metabolites, less platelet inhibition, and lower 
Correlation of CYPʹCͳͻ Polymorphism 
with the Clinical Outcomes in Patients 
Taking Clopidogrel
͵ͺ
The Indonesian Biomedical Journal, Vol.6, No.1, April 2014, p.33-44 ISSN: 2085-3297
risk of bleeding, but there was no signiicant association of 
genotype with cardiovascular events.(44)
 In a response to the article above, Shuldiner et al. 
confronted the small study bias explored by the meta-
analysis. They argued that the small studies pointed tent to 
be those including a higher proportion of patient with stents, 
in whom clopidogrel is more likely to be effective. This is 
also consistent with the meta-analysis by Mega et al. (41), 
involving studies predominantly with patients receiving 
percutaneous coronary intervention (PCI), which found a 
signiicant effect. Shuldiner also argued that an alternative 
interpretation of the meta-analysis by Holmes is that 
CYP2C19 genotype is an important predictor of adverse 
cardiovascular outcome for patient with coronary stent, and 
that it may be less important for patient taking clopidogrel 
for other indication, particularly those in which the drug has 
a smaller overall effect on outcomes (45). 
As has been stated, CYP2C19 genetic variation can only 
explain for about 12-20 % of all variation in clopidogrel 
response. Other genes have been studied including ABCB1/
MDR1 gene, other CYP enzymes (CYP3A4, CYP3A5), 
P2Y12 receptor, and most recently Paraoxonase-1 (PON-1). 
Intestinal absorption of the pro drug clopidogrel is limited 
by an intestinal eflux pump P-glycoprotein coded by the 
ABCB1 gene. There are several reports of an increase in 
the hazard ratio for an outcome event among patients 
carrying the ABCB1 variant allele (genotype CT or TT) as 
compared with the wild-type allele (CC).(36,46) ABCB1 T 
allele is associated with increased intestinal eflux possibly 
mediated by higher P-glycoprotein expression, and a 
reduced concentration of active drug metabolite.(46) On the 
other hand, another study by Wallentin reported contrasting 
result, with a higher rate of primary events for the ABCB1 
3455 CC genotype.(47)
 As the conversion of clopidogrel to its active form 
is also mediated by enzymes other than CYP2C19, it 
was suspected that other enzymes also contribute to the 
variation of clopidogrel response. A study reported that 
CYP3A4 IVS10+12G/A modulated platelet activation, and 
thus may contribute to clopidogrel response variability.(48) 
Cuisset et al. reported that CYP3A4*1B or CYP3A5*3 did 
not correlate with ADP-induced platelet aggregation.(49)
Reports of the role of P2Y12 receptor polymorphism have 
tended to be not associated with a risk of adverse outcome 
(36, 48). 
 The most recently reported gene affecting the eficacy 
of clopidogrel is the PON-1. This enzyme is regarded as 
the crucial enzyme for clopidogrel bioactivation, with its 
common Q192R polymorphism determining the rate of 
active metabolite formation. PON-1 QQ192 homozygous 
individuals showed a considerably higher risk than RR192 
homozygous individuals of stent thrombosis, lower PON-
1 plasma activity, lower plasma concentrations of active 
metabolite and lower platelet inhibition.(50) This report 
has been refuted by two recent studies, re-conforming 
the role of CYP2C19, and not PON-1 in the clopidogrel 
responsiveness.(51,52)  It should also be noted  that  the 
genome-wide  association  study on  clopidogrel eficacy 
did  not  identify  SNPs surrounding or including the PON-1 
locus,  only the area surrounding the CYP2C enzyme cluster 
was associated with diminished clopidogrel response.(33)
Responding to the studies reporting the signiicance of 
CYP2C19 polymorphism to the response of clopidogrel, 
FDA has so far made 3 recommendations on the label of 
the drug.(4) Firstly in May 2009, FDA simply noted that 
“poor metabolizer status is associated with diminished 
response to clopidogrel” and that “the optimal dose for 
poor metabolizers has yet to be determined”. The second 
revision in 2009 advised avoiding the use of clopidogrel 
“in patients with impaired CYP2C19 function due to 
known genetic polymorphisms or due to drugs that inhibit 
CYP2C19 activity” and added additional information about 
the interaction of clopidogrel and omeprazole. In the last 
revision in March 2010, FDA  approved  a  new  label 
for clopidogrel with a “boxed warning” stating “There is 
reduced effectiveness in patients who are poor metabolizers, 
tests are available to identify patients with genetic 
polymorphisms, and that alternative treatment strategies 
should be considered in poor metabolizers of the drug”.(18)
Although the association of genetic polymorphism of 
CYP2C19 with the response of clopidogrel is well-
established, and there are numbers of studies conirming 
the association to the clinical outcomes, how the tests of 
Genetic Factors other than CYPʹCͳͻ FDA recommendation on the label of 
Clopidogrel (Plavix)
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the genetic polymorphism should be prescribed in the 
routine practice is still an unsolved problem. There are still 
questions on what patients should be tested, when to test, 
and what are the alternative treatment for those detected to 
be PM. Increasing the dose of clopidogrel in heterozygote 
loss of function carrier to 225 mg can achieve the level of 
platelet reactivity similar to that seen in standard 75 mg 
dose in non-carrier, but in homozygotes, increase to 300 
mg daily did not result in comparable degrees of platelet 
inhibition. More over this study only measured the platelet 
reactivity, and did not measure the higher dose on the clinical 
outcomes.(53) Several studies have reported that prasugrel 
another thionopyridines is not affected by the CYP2C19 
(54-56), and can be an alternative for the PMs, but this drug 
is also related to more risk of bleeding (57). Ticagrelor has 
been also proposed as an alternative to clopidogrel, which 
is not affected by the CYP2C19 genotypes.(47,58) The 
genetic polymorphism test was reported not yet to offer an 
opportunity to optimize treatment given the current state of 
knowledge (59), but the other reported that genotype-guided 
antiplatelet therapy between clopidogrel and prasugrel may 
be more cost-effective and may provide more clinical value 
due to fewer adverse outcomes.(60) 
PPIs are used to treat acid-related disorder like the gastro 
oesophageal  relux  disease or oesophagitis/gastritis and also 
in eradication of Helicobacter pylori infection together with 
antibiotics.(61) Omeprazole was the irst PPI introduced 
in the market, followed by pantoprazole, lanzoprazole and 
rabeprazole. Though these PPIs share  the  core  structures 
benzimidazole  and  pyridine,  their  pharmacokinetics  and 
pharmacodynamics  are  a  little  different (62). 
 PPIs are metabolized in the liver by CYP, speciically 
CYP2C19 and CYP3A4. Omeprazole for example is mainly 
metabolized to 5-hydroxyomeprazole by CYP2C19 and 
to omeprazole sulphoneby CYP3A4.(63) Ranzoprazole 
is an exception and reported to be only partly CYP2C19 
mediated.(64) 
 Different enantiomer of the drugs also bind the CYP 
enzyme with different afinity. R-omeprazole was more 
sensitive to CYP2C19 while S-omeprazole  was  less 
sensitive. Therefore, S-omeprazole provided better plasma 
level of the drug. Like omeprazole, lansoprazole also  was 
extensively  metabolized  by  CYP2C19  and  CYP3A4.
(62) Individuals with PM CYP2C19 enzymes exhibit a 3 to 
10 folds higher area under the plasmic concentration curve 
(AUC) than homozygote EM (HomEM), while heterozygote 
EM (HetEM) exhibit  a  2  to  3  folds  higher  AUC.(62)
 Evidence of the association between CYP2C19 
polymorphism and the therapy outcomes of PPIs has been 
accumulated (65-68), but lack consistency in terms of the 
association with different PPIs used (64). At least, four meta-
analyses have been conducted to more clearly understand 
this association. 
 In 2006, a meta-analysis including twenty eight arms 
from seventeen papers reported that omeprazole but not 
lanzoprazole or rabeprazole has different treatment eficacy 
based on the CYP2C19 enzyme status. Omeprazole as a 
component of either in dual or triple therapy regiment gives 
better outcome in PM versus HomEM with OD of 4.03 
(95%CI: 1.997-8.28, p=0.0001), and also in PM vs. HetEM 
with OD of 2.24 (95% CI: 1.09-4.61, p=0.03).(69)
 Another meta-analysis performed in 2008 involving 
20 articles reported signiicant higher eradication rate for 
omeprazole and lansoprazole with in PM vs. HomEM (OD 
of 4.28, p=0.0005 for omeprazole and OD of 3.06, p=0.001 
for lansoprazole), and also in HetEM vs. HomEM (OD of 
3.22, p<0.0001 for omeprazole and OD of 1.95, p=0.04 
for lansoprazole). Ranzoprazole was not affected by the 
CYP2C19 genotypes.(70)
 In 2012, McNicchol analyzed 35 studies comprising 
5,998 patients and reported that CYP2C19 genotype did 
not inluence omeprazole, lansoprazole, pantoprazole or the 
newer generation of PPIs, esomeprazole or rabeprazole. But 
in CYP2C19 EM, they found that new generation of PPIs 
might be more effective.(71) 
 Another meta-analysis was reported in 2013 by 
Tang et al. In this newer meta-analysis of 16 randomized 
controlled trials involving 3,680 patients, they found that 
the metabolizer status affects the eficacy of omeprazole, 
with OD of 0.329 (95%CI: 0.195-0.553) for HomEM vs. 
HetEM and 0.232 (95%CI: 0.105-0.515) for HomEM vs. 
PM, and lansoprazole with OD of 0.692 (95% CI: 0.485-
0.988) for HomEM vs. HetEM and 0.441 (95%CI: 0.252-
0.771) for HomEM vs. PM. No difference was observed for 
HetEM vs. PM. In regards to rabeprazole or esomeprazole, 
no class effect of CYP2C19 genotypes was seen.(64)
 Esomeprazole is a pure S-isomer of omerprazole, and 
thus is less sensitive to CYP2C19, and this might explain 
why the eficacy of this drug is not affected by the enzyme. 
Similarly,  rabeprazole  is  metabolized  to  thioether-
rabeprazole mainly  via  a  non-enzymatic  pathway with 
minor  involvement of  CYP2C19, which is consistent with 
CYPʹCͳͻ - Effects on PPIs
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the results of several meta-analyses.(64,69,70) 
PPIs are often prescribed together in patients receiving 
dual anti platelet therapy to prevent the gastrointestinal 
(GI) bleeding. In 2011 American College of Cardiology 
Foundation (ACSF) / American Heart Association (AHA) 
/ Society for Cardiovascular Angiography and Interventions 
(SCAI) Guideline for PCI, PPIs should be used in patients 
with a history of prior GI bleeding who require Dual Anti 
Platelet Therapy (DAPT) (I). 
 This guideline also states that use of PPIs is reasonable 
in patients with an increased risk of GI bleeding (e.g., 
advanced age, concomitant use of warfarin, steroids, non-
steroidal anti-inlammatory drugs (NSAIDs), Helicobacter 
pylori infection) who require DAPT. (IIa), and routine use 
of a PPI is not recommended for patients at low risk of GI 
bleeding, who have much less potential to beneit from 
prophylactic therapy (III, no beneit).(72)
 Some class of PPIs (omeprazole, lansoprazole) are 
metabolized mainly by CYP2C19 and some class of PPI like 
omeprazole and esomeprazole are inhibitors of CYP2C19 
(73-75) with omeprazole being the most potent (73).
Lansoprazole, pantoprazole, and rabeprazole are reported to 
be not inhibiting CYP2C19.(74) 
 The signiicant association of this inhibition effect 
of omeprazole to the attenuated inhibition of platelet 
aggregation when clopidogrel and omeprazole are 
concomitantly used, has been reported by numerous studies.
(76-78) 
 Furuta et al. also reported that besides omeprazole, 
lansoprazole and rabeprazole also affect inhibition of 
platelet activity to some degree (76), but other reports 
showed contrasting results for PPIs other than omeprazole.
(77,79) 
 Several reports have been less consistent regarding 
the clinical effect of this interaction. Some studies have 
reported a signiicant association of concomitant use of 
clopidogrel and PPIs with higher adverse outcomes (80,81), 
while others reported conlicting results (82-85). 
 Another study found only a signiicant association of 
omeprazole with the increased rate of hospitalization, while 
not the case with other PPIs.(79) And two studies focusing 
on patients receiving PCI also could not ind an association 
between use of PPI and clopidogrel with higher adverse 
outcomes.(86,87)
 Two review articles have suggested some possibility 
that may lead to signiicant results by some groups but not 
by the others including higher comorbidities in the group 
using PPIs, age bias, and low quality design of study 
that did not adjust to the confounding factors as in the 
signiicant result groups.(88,89) So far, the only existing 
randomized controlled double-blind multicenter trial is the 
clopidogrel and the optimization of gastrointestinal events 
trial (COGENT), which involved 3,878 patients with acute 
coronary syndrome (ACS) or undergoing PCI. This study 
showed no difference in the occurrence of cardiovascular 
events in clopidogrel+omeprazole group from that in the 
clopidogrel only group, and that the omeprazole signiicantly 
decreased the bleeding risk.(84) 
 However, two other review articles questioned the 
power of this study result to exclude the clinical interaction 
between omeprazole and clopidogrel. Tarnawski pointed 
out the wide CI around the HR of cardiovascular events and 
a possibility of population bias, as 94 % of the COGENT 
subjects are white.(88) Fernando et al. also raised some 
concern regarding the low events of ACS in this study.(89)
 In one meta-analysis on 23 studies covering 93,278 
patients, the authors pointed out that the positive signiicant 
association was reported by observational studies, while 
propensity matched and randomized trials failed to prove 
such association between concomitant use of PPIs and 
clopidogrel with the cardiovascular risk (90). A similar 
result reported by Lima et al., with low quality design 
study reported a signiicant association, while none of the 
moderate or high quality study did (91). 
 Another meta-analysis by Siller-Matula concluded a 
signiicant association with major cardiovascular events, 
but not with mortality. PPIs were also found to associate 
with lower risk of bleeding. (92). These three meta analyses 
pointed out the same point that there was high grade 
of heterogeneity among the studies, including different 
populations, outcomes assessed, drug exposure methods 
and study quality, that might lead to some bias, unmeasured 
confounding factors, and inconsistent results (90-92). 
Lima et al. also analyzed that there was inverse correlation 
between study quality and a reported statistically positive 
interaction. (91)
 Despite inconsistent results, on the label of Plavix, 
FDA has discouraged the use of PPIs (especially omeprazole 
and esomeprazole) concomitantly with clopidogrel, and 
recommend the use of PPIs with lesser inhibitory effect 
to the CYP2C19 (dexlansoprazole, lansoprazole and 
pantoprazole).(4)
Interaction between Clopidogrel and PPIs
 Ͷͳ
Pharmacogenetics of  CYP2C19 - Effect on Clopidogrel and PPI (Liau Y)
Indones  Biomed J.  2014; 6(1): 33-44DOI: 10.18585/inabj.v6i1.41
13. Goldstein JA. Clinical relevance of genetic polymorphisms in the 
human CYP2C subfamily. Brit J ClinPharmacol. 2001; 52: 349-55.
14. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. 
CYP2C19 allele nomenclature. Available at: http: //www.cypalleles.
ki.se/. Accessed March 1, 2014.
15. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer 
UA, Goldstein JA. The major genetic defect responsible for the 
polymorphism of S-mephenytoin metabolism in humans. J Biol 
Chem. 1994; 269: 15419-22.
16. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura 
K, Goldstein JA. Identiication of a new genetic defect responsible 
for the polymorphism of (S) -mephenytoin metabolism in Japanese. 
Mol Pharmacol. 1994; 46: 594-8 (Abstract).
17. Ozdil B, Akkiz H, Bayram S, Bekar A, Akgoll E, Sandikci M. 
Inluence of CYP2C19 functional polymorphism on Helicobacter 
pylori eradication. Turk J Gastroenterol 2010; 21: 23-28.
18. Holmes DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. 
ACCF/AHA clopidogrel clinical alert: approaches to the FDA 
“Boxed Warning”: a report of the American College of Cardiology 
Foundation Task Force on clinical expert consensus documents and 
the American Heart Association. Circulation. 2010; 122: 537-57.
19. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 
Allele on the pharmacokinetics of omeprazole and pantoprazole 
in children: evidence for a differential Effect. Drug MetabDispos. 
2010; 38:894–97.
20. Sim SC , Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson 
L, et al. Common novel CYP2C19 gene variant causes ultrarapid 
drug metabolism relevant for the drug response to proton pump 
inhibitors andantidepressants. ClinPharmacolTher. 2006; 79: 103-
13 (Abstract).
21. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. 
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding 
events, and stent thrombosis in clopidogrel-treated patients with 
coronary stent placement. Circulation. 2010; 121: 512-18.
22. Lyon E, Foster JG, Palomaki GE, Pratt VM, Reynolds K, Sabato MF, 
et.al, Laboratory testing of CYP2D6 alleles in relation to tamoxifen 
therapy. Genet Med. 2012; 14: 990-1000.
23.  Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein 
CM, et al. Clinical pharmacogeneticsimplementation consortium 
guidelines for CYP2C9 and VKORC1 genotypes and warfarin 
dosing. ClinPharmacolTher. 2011; 90: 625-29.
24. Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, 
Krishnamoorthy R. Allele and genotype frequency of CYP2C19 in 
a Tamilian population. J ClinPharmacol. 2003; 56: 331-33.
25. Strom CM, Goos D, Crossley B, Zhang K, Buller-Burkle A, Jarvis M, 
et al. Testing for variants in CYP2C19: population frequencies and 
testing experience in a clinical laboratory. Genet Med. 2012; 14:95-
100.
26. Yusmiati, Mulatsih R, Fattah M, Santoso A, Sukmawan R, Soedarmo. 
Assessment of CYP2C19 *2 and *3 genetic polymorphisms 
frequencies in Indonesian population using PCR-RFLP method. 
13th Asian Paciic Federation of Clinical Biochemistry Congress 
2013 (Poster). 
27. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black 
C. Antiplateletagentsaspirin and clopidogrel are hydrolyzed by 
distinctcarboxylesterases, and clopidogrel is transesteriicated in the 
presence of ethylalcohol. J PharmacolExpTher.2006; 319: 1467-76.
28. Sangkuhl K, Kleina TE, Altmana RB. Clopidogrel pathway. 
Pharmacogenet Genomics. 2010; 20: 463-5.
29. Kazui M, Nichiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et 
al. Identiication of the human cytochrome P450 enzymes involved 
in the two oxidative steps in the bioactivation of clopidogrel to its 
Conclusion
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